title: Treatment patterns in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
abstract: BACKGROUND
  The Antiplatelet Therapy Observational Registry (APTOR) is a prospective observational study of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) in a 'real world' clinical setting. Here the authors report on the management of ACS patients in three European countries during the hospital phase and through 12-months' follow-up, including use of antiplatelet agents, co-medications and stents, as well as clinical outcomes at 12 months.
  
  
  METHODS
  ACS patients undergoing PCI (N = 1525) from January to August 2007 were planned to be consecutively recruited in France, Spain and the UK.
  
  
  RESULTS
  Index diagnosis was unstable angina/non-ST-segment elevation myocardial infarction (MI) in 62% and ST-segment elevation MI in 38%. Prior to the index ACS event, 17% were prescribed both aspirin and clopidogrel. While in-hospital clopidogrel and aspirin use was similar across countries, considerable variation was observed between countries at 12 months (clopidogrel 66-75%; aspirin 86-95%). The UK most frequently used a 300-mg clopidogrel loading dose (70%) compared with France (53%) and Spain (56%), while >300 mg was used in 21%, 34% and 16% patients, respectively. Bare metal stents only were used in 42% of subjects, drug-eluting stents (DES) only in 40%, and both in 10%, with the highest rates of DES use in Spain (70%) followed by the UK (47%) and France (31%). The composite endpoint of cardiovascular (CV) death, MI or stroke occurred in 4.7% of patients by 12 months.
  
  
  CONCLUSIONS
  APTOR shows marked variation in ACS management between countries in antiplatelet therapy, co-medications and stent use. Due to the observational design of the registry, statistical testing was not applied and data should be seen as hypothesis generating. These data provide a useful benchmark for comparison with current guidelines.
authors.affiliation: Toulouse Rangueil University Hospital, Toulouse, France.
authors.forename: Jean
authors.initials: J
authors.lastname: Ferrieres
authors.forename: Ameet
authors.initials: A
authors.lastname: Bakhai
authors.forename: Andres
authors.initials: A
authors.lastname: Iñiguez
authors.forename: Claude
authors.initials: C
authors.lastname: Schmitt
authors.forename: Magali
authors.initials: M
authors.lastname: Sartral
authors.forename: Mark
authors.initials: M
authors.lastname: Belger
authors.forename: Uwe
authors.initials: U
authors.lastname: Zeymer
mesh_terms: D054058:Acute Coronary Syndrome / Q000453:epidemiology / Q000628:therapy*; D000368:Aged; D054855:Drug-Eluting Stents / Q000706:statistics & numerical data; D057510:Endovascular Procedures / Q000379:methods* / Q000706:statistics & numerical data; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011364:Professional Practice; D012042:Registries; D013030:Spain; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D010975:Platelet Aggregation Inhibitors